Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen
Clinical trial NCT04837196 · COMPLETED
Trial details
- NCT number
- NCT04837196
- Sponsor
- Astellas Pharma Global Development, Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-11
- Primary completion
- 2024-06-21
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.